02158 YIDU TECH
- 4.210
- -0.090-2.09%
YIDU TECH News
Huajin Securities gave Yidu Technology (02158) a purchase rating: self-developed big model released and joined hands with Huawei to build an ecosystem
Yidu Technology (2158.HK): Self-developed large-scale language models in the vertical field of medical care empowers YIDUCORE diabetes digital therapy to make positive progress
Changes in Hong Kong stocks | Yidu Technology (02158) rose more than 8%, and the three major banks gave the company a “buy” rating
Yidu Technology (02158.HK): Losses have been drastically reduced, intelligent clinical competitiveness is outstanding
Goldman Sachs, Citigroup, and Daiwa maintain Yidu Technology (02158) “buy” ratings
Yidu Technology (2158.HK): Losses have been drastically reduced, and the medical model is progressing steadily
CICC is optimistic that the company will open up diversified monetization space in the intelligent transformation of medical care. For the first time, it covered Yidu Technology (02158) and was rated “outperform the industry” for the first time
Guotai Junan: Maintain Medicudu Technology's (02158) “increase holdings” rating with a target price of HK$11.26
Everbright Securities: First Yidu Technology (02158) “Buy” Rating to Empower Healthcare Big Data Solutions with YiDuCore
Medical Ferry Technology (2158.HK): The medical big data market space is broad, and medical AI applications can be expected
Yidu Technology (2158.HK) FY2022 Annual Performance Review Report: Healthcare Big Data Infrastructure Is Steadily Expanding and Revenue Structure Becoming More Balanced
Yidu Technology (2158.HK): The synergies between the three business segments are worth looking forward to
Yidu Technology (02158.HK): Revenue growth exceeds expectations, and the three major business segments are working together
Yidu Technology (2158.HK) FY2022 Interim Results Review Report: Steady Expansion of Medical Big Data Infrastructure Drives Diversified Growth
Yidu Technology (2158.HK): Three sectors merged to verify profit models with rising gross margin
Yidu Technology (2158.HK) FY2021 Annual Performance Review Report: Relying on YIDUCORE Big Data Infrastructure to Start Diversified Growth
Overseas Healthcare Sector Weekly Report: The task of deepening medical reform in 2021, CUREVAC COVID-19 vaccine development failed
Medical Ferry Technology (2158.HK): Using YIDUCORE as the base to become a service provider in all fields of medical data
Yidu Technology (2158.HK) Investment Value Analysis Report: Leading Medical Big Data Leaders Take Advantage of Digitalization with YIDUCORE as Core
Medical Ferry Technology (2158.HK): Focusing on medical information services with YIDUCORE as the core
Analysis
Price Target
No Data
